MedTrace Logo

Optimized Antiplatelet Therapy on the Prognosis of ACS Patients With Non-predominant Coronary Artery Disease After PCI

NCT04338919 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2020

Last updated 2020-05-13

No results posted yet for this study

Summary

The study is to evaluate the effect of optimized 12-month step-down antiplatelet therapy (APT) compared with standard 12-month dual antiplatelet therapy in clinical net adverse events, cardiovascular and cerebrovascular adverse events and reducing clinical related bleeding events in the patients with acute coronary syndrome (ACS) who are not the predominant coronary artery disease after percutaneous coronary intervention (PCI).

Conditions

  • Acute Coronary Syndrome
  • Percutaneous Coronary Intervention

Interventions

PROCEDURE

Percutaneous coronary intervention

PCI with stent implantation

DRUG

Ticagrelor plus aspirin

Ticagrelor plus aspirin

Sponsors & Collaborators

  • Fujian Medical University

    lead OTHER

Principal Investigators

  • Chen Lianglong, MD, PhD · Fujian Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-14
Primary Completion
2021-04-01
Completion
2023-04-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04338919 on ClinicalTrials.gov